drugset / Press release
Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
2024-06-04 · Ono Pharmaceutical Co., Ltd. · original ono-pharma.com ↗
This material is intended to notify the press release issued on May 29 (local time) by Bristol Myers Squibb, our license partner for Opdivo. Please click https://www.bms.com/media/press-releases.html for the original press release.
The release as fetched from its publisher. ono-pharma.com ↗